HomeAerin Medical Inc.

Aerin Medical Inc.

FDA Clearance and U.S. Launch of Innovative Nonsurgical Procedure for Chronic Rhinitis

The RhinAer™ Stylus, an innovative device for nonsurgical treatment of chronic rhinitis.

Aerin Medical Inc. Secures $50 Million Debt Facility

Aerin received $35 million at closing and will receive an additional $15 million in two tranches upon achieving certain milestones. The Company used approximately $16.5 million of these proceeds to retire its existing debt. The remaining proceeds will be used to accelerate Aerin's sales and marketing reach and to launch its next product.